Second primary malignancy among older adults with multiple myeloma receiving fi rst -line lenalidomide-based therapy: A population-based analysis

摘要

Objectives: Clinical trials have suggested that patients with myeloma treated with lenalidomide may have an increased risk of second primary malignancies (SPM). Whether such risks are of significant relevance in the real world clinical practice, particularly among older patients receiving first-line lenalidomide based therapy, remains unclear.